NASDAQ:OTIC

Otonomy - OTIC Stock Forecast, Price & News

$0.28

0.00 (0.00%)

(As of 09/26/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.27
▼
$0.34
50-Day Range: $0.25
▼
$2.22
52-Week Range: $0.24
▼
$2.59

Volume: 459,748 shs
Average Volume: 696,438 shs
Market Capitalization: $15.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

Otonomy MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 1,515.8% Upside
$4.50 Price Target
Short Interest: Healthy
1.32% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.25
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.73) to ($0.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

550th out of 1,069 stocks

Pharmaceutical Preparations Industry

253rd out of 533 stocks

3.3

Analyst's Opinion

Consensus Rating
Otonomy has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.50, Otonomy has a forecasted upside of 1,515.8% from its current price of $0.28.
Amount of Analyst Coverage
Otonomy has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.32% of the float of Otonomy has been sold short.
Short Interest Ratio / Days to Cover
Otonomy has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Otonomy has recently increased by 66.24%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Otonomy does not currently pay a dividend.
Dividend Growth
Otonomy does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OTIC.

1.8

News and Social Media Coverage

News Sentiment
Otonomy has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Otonomy this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for OTIC on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Otonomy insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.10% of the stock of Otonomy is held by insiders.
Percentage Held by Institutions
80.05% of the stock of Otonomy is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Otonomy are expected to grow in the coming year, from ($0.73) to ($0.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Otonomy is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Otonomy is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Otonomy has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

September 20, 2022 | americanbankingnews.com

Otonomy (NASDAQ:OTIC) Receives New Coverage from Analysts at StockNews.com

September 9, 2022 | streetinsider.com

Form SC 13G/A OTONOMY, INC. Filed by: FEDERATED HERMES, INC. - StreetInsider.com

September 1, 2022 | finance.yahoo.com

AGTC to Participate in Upcoming Investor Conferences - Yahoo Finance

August 6, 2022 | benzinga.com

Short Volatility Alert: Otonomy, Inc. - Benzinga

August 2, 2022 | seekingalpha.com

OTIC stock downgraded at H.C. Wainwright as tinnitus candidate fails (NASDAQ:OTIC) - Seeking Alpha

August 2, 2022 | uk.investing.com

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial By Benzinga - Investing.com UK

August 2, 2022 | marketwatch.com

Otonomy Shares Plumb New Depths on Failure of Lead Program >OTIC - MarketWatch

August 1, 2022 | seekingalpha.com

Virax, Aethlon top healthcare gainers; while Otonomy, Kazia lead losers' pack - Seeking Alpha

August 1, 2022 | finance.yahoo.com

Otonomy Shares Sink After Stopping Mid-Stage Tinnitus Study

August 1, 2022 | benzinga.com

Otonomy Reports Results From Phase 2 Clinical Trial Of OTO-313 In Patients With Tinnitus; Co. Reports 'OT - Benzinga

August 1, 2022 | globenewswire.com

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus - GlobeNewswire

August 1, 2022 | finance.yahoo.com

Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus

July 30, 2022 | americanbankingnews.com

Otonomy (NASDAQ:OTIC) Research Coverage Started at StockNews.com

July 27, 2022 | nasdaq.com

Walmart Cuts Q2, FY Profit Outlook; Stock Down - Nasdaq

July 27, 2022 | finance.yahoo.com

Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platform for Drug Design - Yahoo Finance

July 26, 2022 | benzinga.com

Otonomy shares are trading lower after the company reported Q2 earnings results. - Benzinga - Benzinga

July 26, 2022 | rttnews.com

HealthStream EPS Tops Estimate, MEDP Revises Forecast, OTIC To Report Tinnitus Trial Data In August - RTTNews

July 26, 2022 | globenewswire.com

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update - GlobeNewswire

July 25, 2022 | finance.yahoo.com

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 22, 2022 | benzinga.com

Otonomy's Earnings Outlook - Benzinga - Benzinga

July 22, 2022 | seekingalpha.com

Otonomy Q2 2022 Earnings Preview - Seeking Alpha

July 21, 2022 | businesswire.com

Tinnitus Pipeline Research Report 2022: Comprehensive Insights About 8+ Companies and 8+ Pipeline Drugs - ResearchAndMarkets.com - Business Wire

July 18, 2022 | rttnews.com

Pre-market Movers: ILAG, USEA, TSLX, EVTL, ITHX… - RTTNews

July 18, 2022 | finance.yahoo.com

Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update

May 18, 2022 | finance.yahoo.com

Otonomy to Participate in the H.C. Wainwright Global Investment Conference

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Company Calendar

Last Earnings: 7/25/2022
Today: 9/26/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:OTIC
CUSIP: N/A
CIK: 1493566
Web: www.otonomy.com
Phone: (619) 323-2200
Fax: 619-291-9190
Employees: 51
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.50
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +1,515.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,180,000.00
Net Margins: N/A
Pretax Margin: -150,065.70%
Return on Equity: -107.93%
Return on Assets: -60.24%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 4.83
Quick Ratio: 4.83

Sales & Book Value

Annual Sales: $130,000.00
Price / Sales: 122.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 56,990,000
Free Float: 51,804,000
Market Cap: $15.87 million
Optionable: Optionable
Beta: 1.49

Key Executives

Dr. David Allen Weber (Age 62)
Pres, CEO & Director
Comp: $907.68k

Mr. Paul E. Cayer (Age 60)
Chief Financial & Bus. Officer
Comp: $598.22k

Mr. Robert Michael Savel II (Age 54)
Chief Technical Officer
Comp: $534.58k

Dr. Allen F. Ryan Ph.D.
Co-Founder and Member of the Advisory Panel

Dr. Rick Adam Friedman M.D.
Ph.D., Co-Founder and Member of the Advisory Panel

Dr. Alan Charles Foster Ph.D. (Age 66)
Chief Scientific Officer

Ms. Breianna Bowen
VP of HR

Ms. Barbara M. Finn
Sr. VP of Regulatory Affairs & Quality Assurance

Dr. Fabrice Piu Ph.D.
Sr. VP of Preclinical Devel.

Mr. David Skarinsky
Sr. VP of Clinical

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OTIC shares.
View OTIC analyst ratings or view top-rated stocks.
What is Otonomy's stock price forecast for 2022?: 3 equities research analysts have issued 12-month price targets for Otonomy's shares. Their OTIC share price forecasts range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 1,400.0% from the stock's current price.
View analysts price targets for OTIC or view top-rated stocks among Wall Street analysts.
How have OTIC shares performed in 2022?: Otonomy's stock was trading at $2.08 at the beginning of the year. Since then, OTIC shares have decreased by 85.6% and is now trading at $0.30.
View the best growth stocks for 2022 here.
When is Otonomy's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our OTIC earnings forecast.
How were Otonomy's earnings last quarter?: Otonomy, Inc. (NASDAQ:OTIC) announced its quarterly earnings data on Monday, July, 25th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. During the same quarter in the prior year, the company posted ($0.19) earnings per share.

What other stocks do shareholders of Otonomy own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().
What is Otonomy's stock symbol?: Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
Who are Otonomy's major shareholders?: Otonomy's stock is owned by a variety of retail and institutional investors. Top institutional investors include DAFNA Capital Management LLC (2.58%), Silverarc Capital Management LLC (1.83%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Allen Weber, Jay Lichter and Robert Michael Savel II.
View institutional ownership trends.
How do I buy shares of Otonomy?: Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Otonomy's stock price today?: One share of OTIC stock can currently be purchased for approximately $0.30.
How much money does Otonomy make?: Otonomy (NASDAQ:OTIC) has a market capitalization of $17.10 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.
How can I contact Otonomy?: Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Otonomy - OTIC Stock Forecast, Price & News

Otonomy MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month